The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.
1. A method for protecting a porcine animal against infection caused by Mycoplasma hyopneumoniae comprising administering to said porcine animal a vaccine composition which comprises:
an immunizing amount of Mycoplasma hyopneumoniae bacterin,
an adjuvant mixture comprising an acrylic acid polymer and a mixture of metabolizable oil and a polyoxyethylene-polyoxypropylene block copolymer and
a pharmaceutically acceptable carrier, wherein said vaccine composition, after a single administration, elicits protective immunity lasting for six months in said porcine animal against said Mycoplasma hyopneumoniae infection.
2. The method of claim 1 , wherein the immunizing amount of said bacterin is about 1×10 8 to 3×10 11 Mycoplasma hyopneumoniae DNA Cell equivalents (MHDCE)/mL.
3. The method according to claim 2 wherein the immunizing amount of said bacterin is about 1×10 9 to 3×10 9 MHDCE/mL.
4. The method of claim 1 , wherein the vaccine composition is administered by intramuscular, subcutaneous, intraperitoneal, aerosol or intranasal route.
5. The method of claim 1 , wherein the adjuvant mixture consists of an acrylic acid polymer and a mixture of metabolizable oil that comprises one or more terpene hydrocarbons and a polyoxyethylene-polyoxypropylene block copolymer present in a final concentration of about 1-25% v/v.
6. The method of claim 5 , wherein the acrylic acid polymer of the adjuvant mixture is a polymer of acrylic acid cross-linked with polyallylsucrose having the chemical formula (CH 2 CHOOOH) n .
7. The method of claim 5 , wherein the metabolizable oil of the adjuvant mixture is a terpene hydrocarbon selected from the group consisting of squalene and squalane.
8. The method as in any of claims 1 - 7 , further comprising coadministering at least one additional bacterin selected from the group consisting of Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis and leptospira.